The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast ...
BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.
Related Clinical Trials
Highlighted Terms
venetoclax [Venclexta]NCT02454972topotecandocetaxellurbinectedin (Zepzelca)extensive-stage small cell lung cancer (ES-SCLC)small lymphocytic lymphoma (SLL)FDAFred Hutch Cancer CenterWake Forest School of MedicinepaclitaxelAtrium Health Levine Cancer Institutechronic lymphocytic leukemia (CLL)Emory University School of MedicineNCT04277637BGB-16673University of Washington School of MedicineNCT05060016BeiGeneNCT05006716sonrotoclax (BGB-11417)obinutuzumab (Gazyva)HER2-positive breast cancerzanubrutinib (Brukinsa)Yale Cancer CenterYale School of MedicineNCT02566993
Related News
The Targeted Pulse: Good News for Advanced CLL/SLL With BGB-16673 Receiving Fast ...
BGB-16673 received FDA fast-track designation for R/R CLL/SLL, potentially eligible for accelerated approval. Sonrotoclax combined with zanubrutinib showed improved responses in R/R CLL/SLL. Lurbinectedin vs topotecan data in ES-SCLC explored. Financial toxicity addressed through a tumor board. Clinicians discuss paclitaxel vs docetaxel in HER2-positive breast cancer.